EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

Cancer Treatment and Research Communications

ISSN 2468-2942 · Elsevier BV

Latest articles

  1. Corrigendum to ’Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer’ [Cancer Research and Treatment Communications 46 (2026) 101112]

    Jesus Edgardo Hernandez-Hernandez, César Octavio Lara-Torres, Alejandro Aranda-Gutiérrez, Víctor A. Domínguez-Porras, Bryan Moreno-Moran, Héctor Díaz-Pérez, Gabriela Sofía Gómez-Macías, Paula Cabrera-Galeana, Cynthia Villarreal-Garza, Alejandro Mohar

    Published: 2026DOI: 10.1016/j.ctarc.2026.101149

  2. A viable human lung cancer tissue collection (LCTC) to accelerate translational research

    Virginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, Federica Pedica, Pierluigi Novellis, Piergiorgio Muriana, Francesca Rita Ogliari, Silvia Teresa Riva, Nerina Shahi, Arianna Limongelli, Laura Bettini, Francesca Rossetti, Stefano Viscardi, Carlo Di Giovannantonio, Francesca Misceo, Cinzia Scala, Riccardo Di Fonzo, Alberto Antonicelli, Alessandro Bandiera, Martina Bellantoni, Simona De Santis, Elisa Dieci, Angelo Carretta, Paola Ciriaco, Pau Mateo-Ramos, Maria Giulia Cangi, Emanuela Brunetto, Lorenza Pecciarini, Gilda Magliacane, Gianluigi Arrigoni, Claudio Doglioni, Roberto Ferrara, Sara Oresti, Maria Grazia Viganò, Antonio Nuccio, Francesco Maria Venanzi, Ludovica Mollica, Giuseppe Damiano, Elena Brioschi, Michele Ferrara

    Published: 2026DOI: 10.1016/j.ctarc.2026.101162

Volumes

2026 · 4832025 · 1722024 · 872023 · 1092022 · 1592021 · 2292020 · 1002019 · 322018 · 312017 · 312016 · 28

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.